Company: DVAX
Filing Date: 2025-02-20
Form Type: DEFA14A
Source: 0001193125-25-029819
Chunk: 1

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-02-20
Form: DEFA14A
Chunk 1
---
4 (§ 240.12b-2of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

| Item 8.01 | Other Events. |

On February 19, 2025, Dynavax Technologies Corporation (the “Company”) issued a press release in response to a stockholder’s purported nomination of candidates to stand for election to the Company’s Board of Directors at the Company’s 2025 Annual Meeting of Stockholders. A copy of the press release is attached as Exhibit 99.1 to this Current Report on 8-K.

| Item 9.01 | Financial Statements and Exhibits. |

(d) Exhibits

| Exhibit 
 Number  
 99.1    |     | Exhibit Description                                                          
 Press Release Dated February 19, 2025.                                       |
|:--------|:----|:-----------------------------------------------------------------------------|
| 104     |     | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| Date: February 19, 2025 |     | By: |     | Dynavax Technologies Corporation 
 /s/ RYAN SPENCER                 |
|:------------------------|:----|:----|:----|:---------------------------------|
|                         |     |     |     | RYAN SPENCER Chief Executive     
 Officer                          |

Exhibit 99.1 Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif., Feb . 19, 2025 –Dynavax Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value. The Company also confirmed that Deep Track Capital (“Deep Track”) has submitted a letter purporting to nominate four candidates to stand for election to the Dynavax Board of Directors at the Company’s 2025 Annual Meeting of Stockholders. Track Record of Strong Financial